Castro Felipe A, Jansen Lina, Krilaviciute Agne, Katalinic Alexander, Pulte Dianne, Sirri Eunice, Ressing Meike, Holleczek Bernd, Luttmann Sabine, Brenner Hermann
Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Institute of Cancer Epidemiology, University of Lübeck, Lübeck, Germany.
J Gastroenterol Hepatol. 2015 Oct;30(10):1485-91. doi: 10.1111/jgh.12989.
This study aims to examine survival for gastric lymphomas and its main subtypes, mucosa-associated lymphoid tissue lymphoma (MALT), and diffuse large B-cell lymphoma (DLBCL), in Germany and in the United States.
Data for patients diagnosed in 1997-2010 were used from 10 population-based German cancer registries and compared to the data from the US Surveillance, Epidemiology and End Results (SEER) 13 registries database. Patients age 15-74 diagnosed with gastric lymphomas were included in the analysis. Period analysis and modeled period analysis were used to estimate 5-year and 10-year relative survival (RS) in 2002-2010 and survival trends from 2002-2004 to 2008-2010.
Overall, the database included 1534 and 2688 patients diagnosed with gastric lymphoma in 1997-2010 in Germany and in the United States, respectively. Survival was substantially higher for MALT (5-year and 10-year RS: 89.0% and 80.9% in Germany, 93.8% and 86.8% in the United States) than for DLBCL (67.5% and 59.2% in Germany, and 65.3% and 54.7% in the United States) in 2002-2010. Survival was slightly higher among female patients and decreased by age for gastric lymphomas combined and its main subtypes. A slight, nonsignificant, increase in the 5-year RS for gastric lymphomas combined was observed in Germany and the United States, with increases in 5-year RS between 2002-2004 and 2008-2010 from 77.1% to 81.0% and from 77.3% to 82.0%, respectively. Five-year RS of MALT exceeded 90% in 2008-2010 in both countries.
Five-year RS of MALT meanwhile exceeds 90% in both Germany and the United States, but DLBCL has remained below 70% in both countries.
本研究旨在调查德国和美国胃淋巴瘤及其主要亚型黏膜相关淋巴组织淋巴瘤（MALT）和弥漫性大B细胞淋巴瘤（DLBCL）的生存率。
使用来自10个德国基于人群的癌症登记处1997 - 2010年诊断患者的数据，并与美国监测、流行病学和最终结果（SEER）13个登记处数据库的数据进行比较。分析纳入年龄在15 - 74岁诊断为胃淋巴瘤的患者。采用时期分析和模型化时期分析来估计2002 - 2010年的5年和10年相对生存率（RS）以及2002 - 2004年至2008 - 2010年的生存趋势。
总体而言，该数据库分别纳入了德国和美国1997 - 2010年诊断为胃淋巴瘤的1534例和2688例患者。在2002 - 2010年期间，MALT的生存率（5年和10年RS：德国分别为89.0%和80.9%，美国分别为93.8%和86.8%）显著高于DLBCL（德国分别为67.5%和59.2%，美国分别为65.3%和54.7%）。胃淋巴瘤总体及其主要亚型在女性患者中的生存率略高，且随年龄增长而降低。德国和美国观察到胃淋巴瘤总体的5年RS略有增加但不显著，2002 - 2004年至2008 - 2010年期间5年RS分别从77.1%增至81.0%和从77.3%增至82.0%。在2008 - 2010年，两国MALT的5年RS均超过90%。
德国和美国MALT的5年RS均同时超过90%，但两国DLBCL的5年RS均仍低于70%。
